Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung

University of North Carolina, Chapel Hill12 enrolled

Overview

The purpose of this research study is to test the ability of Mucinex, an oral, over-the-counter, FDA approved expectorant) to stimulate the clearance of inhaled particles from the subject's lungs (called "mucociliary clearance"). The study will also monitor the metabolism of the drug by the subject's body.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Mucociliary Clearance

Interventions

Mucinex 1200mgDRUG

Compared to Placebo

PlaceboDRUG

Compare to active Mucinex

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy * Non smoker * BMI 19-29 * Normal lung function Exclusion Criteria: * Pregnant * Smokers * Any illness

Locations (1)

UNC Center for Environmental Medicine, Asthma and Lung Biology

Chapel Hill, North Carolina, United States

Outcomes

Primary Outcomes

Difference between drug and placebo in the percentage of particles cleared from the lung.

Time frame: Measurements at 60, 90 and 180 min

Difference between drug and placebo as an estimate of small airway clearance.

Time frame: Measurements at 60, 90 and 180 min

Difference between drug and placebo between study days.

Time frame: Measurements at 60, 90 and 180 min

Secondary Outcomes

Blood will be drawn to determination of guaifenesin in the serum.

Time frame: at baseline and every 30 min x8

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.